Supplemental Table 1.
Severity Categories of Anxiety, Depression, Insomnia, and Distress in Patients With BC
| Severity Category | Total, N (%) | Marital Status |
Close Contact With Patient With COVID-19 |
CVC Flushing |
BC Diagnosis Time |
Annual Income |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) |
P Value | N (%) |
P Value | N (%) |
P Value | N (%) |
P Value | N (%) |
P Value | |||||||||
| Married | Singlea | Yes | No | N/A | Delay Over 4 Weeks | Delay Less Than 4 Weeks | No CVC | ≤1 Year | >1 Year | ≤$15,000 | >$15,000 | |||||||
| GAD-7, anxiety symptoms | ||||||||||||||||||
| Normal | 287 (43.6) | 255 (43.7) | 32 (43.2) | .881 | 18 (37.5) | 252 (44.8) | 17 (35.4) | .079 | 61 (43.4) | 45 (43.7) | 181 (47.4) | .002 | 123 (41.6) | 164 (45.3) | .029 | 243 (43.9) | 44 (42.3) | .327 |
| Mild | 224 (34.0) | 199 (34.1) | 25 (33.8) | 15 (31.2) | 189 (33.6) | 20 (41.7) | 52 (33.3) | 38 (34.4) | 134 (35.1) | 99 (33.4) | 125 (34.5) | 180 (32.4) | 44 (42.3) | |||||
| Moderate | 88 (13.4) | 78 (13.3) | 10 (13.5) | 13 (27.1) | 70 (12.5) | 5 (10.4) | 26 (13.2) | 20 (13.5) | 42 (11.0) | 39 (13.2) | 49 (13.6) | 79 (14.3) | 9 (8.7) | |||||
| Severe | 59 (9.0) | 52 (8.9) | 7 (9.5) | 2 (4.2) | 51 (9.1) | 6 (12.5) | 25 (10.1) | 9 (8.4) | 25 (6.5) | 35 (11.8) | 24 (6.6) | 52 (9.4) | 7 (6.7) | |||||
| PHQ-9, depression symptoms | ||||||||||||||||||
| Normal | 347 (52.7) | 314 (53.8) | 33 (44.6) | .205 | 20 (41.7) | 308 (54.8) | 19 (39.6) | .027 | 80 (56.6) | 52 (50.7) | 215 (56.3) | .004 | 150 (50.7) | 197 (54.4) | .034 | 289 (52.2) | 58 (55.8) | .393 |
| Mild | 166 (25.2) | 146 (25.0) | 20 (27.0) | 14 (29.2) | 135 (24.0) | 17 (35.4) | 26 (21.9) | 31 (27.0) | 109 (28.5) | 72 (24.3) | 94 (26.0) | 136 (24.5) | 30 (28.8) | |||||
| Moderate | 84 (12.8) | 72 (12.3) | 12 (16.2) | 9 (18.7) | 68 (12.1) | 7 (14.6) | 36 (12.7) | 15 (12.8) | 33 (8.6) | 40 (13.5) | 44 (12.1) | 74 (13.4) | 10 (9.6) | |||||
| Severe | 61 (9.3) | 52 (8.9) | 9 (12.2) | 5 (10.4) | 51 (9.1) | 5 (10.4) | 22 (8.8) | 14 (9.5) | 25 (6.6) | 34 (11.5) | 27 (7.5) | 55 (9.9) | 6 (5.8) | |||||
| ISI, insomnia symptoms | ||||||||||||||||||
| Normal | 309 (47.0) | 278 (47.6) | 31 (41.9) | .193 | 23 (47.9) | 272 (48.4) | 14 (29.2) | .092 | 67 (46.9) | 51 (47.0) | 191 (50.0) | .112 | 134 (45.3) | 175 (48.3) | .220 | 252 (45.5) | 57 (54.8) | .099 |
| Mild | 238 (36.2) | 214 (36.6) | 24 (32.4) | 16 (33.3) | 200 (35.6) | 22 (45.8) | 55 (38.2) | 45 (35.1) | 138 (36.1) | 111 (37.5) | 127 (35.1) | 205 (37.0) | 33 (31.7) | |||||
| Moderate | 85 (12.9) | 73 (12.5) | 12 (16.2) | 9 (18.8) | 66 (11.7) | 10 (20.8) | 34 (9.6) | 11 (14.7) | 40 (10.5) | 41 (13.8) | 44 (12.2) | 73 (13.2) | 12 (11.6) | |||||
| Severe | 26 (3.9 | 19 (3.3) | 7 (9.5) | 0 (0) | 24 (4.3) | 2 (4.2) | 8 (5.3) | 5 (3.2) | 13 (3.4) | 10 (3.4) | 16 (4.4) | 24 (4.3) | 2 (1.9) | |||||
| IES-R, distress symptoms | ||||||||||||||||||
| Normal | 112 (17.0) | 99 (17.0) | 13 (17.5) | .920 | 5 (10.4) | 105 (18.7) | 2 (4.2) | .004 | 31 (17.1) | 11 (17.0) | 70 (18.3) | .056 | 38 (12.8) | 74 (20.4) | .177 | 92 (16.6) | 20 (19.2) | .243 |
| Mild | 202 (30.7) | 179 (30.6) | 23 (31.1) | 13 (27.1) | 176 (31.3) | 13 (27.1) | 41 (32.0) | 37 (30.0) | 124 (32.5) | 96 (32.4) | 106 (29.3) | 170 (30.7) | 32 (30.8) | |||||
| Moderate | 207 (31.5) | 188 (32.2) | 19 (25.7) | 18 (37.5) | 172 (30.6) | 17 (35.4) | 44 (31.6) | 43 (31.4) | 120 (31.4) | 100 (33.8) | 107 (29.6) | 171 (30.9) | 36 (34.6) | |||||
| Severe | 137 (20.8) | 118 (20.2) | 19 (25.7) | 12 (25.0) | 109 (19.4) | 16 (33.3) | 48 (19.3) | 21 (21.6) | 68 (17.8) | 62 (21.0) | 75 (20.7) | 121 (21.8) | 16 (15.4) | |||||
| Severity category | Total, N (%) | Residence |
Age, y |
Education |
History of BC Surgery |
BC Molecular Subtype |
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N (%) |
P Value | N (%) |
P Value | N (%) |
P Value | N (%) |
P Value | N (%) |
P Value | ||||||||
| Urban | Rural | ≤55 | >55 | Middle School or Less | High School or Higher | Yes | No | TNBC and HER2 | Luminal | N/A | |||||||
| GAD-7, anxiety symptoms | |||||||||||||||||
| Normal | 287 (43.6) | 212 (43.7) | 75 (43.3) | .576 | 222 (43.0) | 65 (45.8) | .645 | 99 (43.4) | 188 (43.7) | .937 | 274 (43.6) | 13 (43.3) | .387 | 134 (41.4) | 75 (42.4) | 78 (49.4) | .126 |
| Mild | 224 (34.0) | 163 (33.6) | 61 (35.3) | 183 (35.5) | 41 (28.9) | 76 (33.3) | 148 (34.4) | 216 (34.4) | 8 (26.7) | 103 (31.9) | 74 (41.8) | 47 (29.7) | |||||
| Moderate | 88 (13.4) | 66 (13.6) | 22 (12.7) | 67 (13.0) | 21 (14.8) | 30 (13.2) | 58 (13.5) | 85 (13.6) | 3 (10.0) | 48 (14.9) | 19 (10.7) | 21 (13.3) | |||||
| Severe | 59 (9.0) | 44 (9.1) | 15 (8.7) | 44 (8.5) | 15 (10.5) | 23 (10.1) | 36 (8.4) | 53 (8.4) | 6 (20.0) | 38 (11.8) | 9 (5.1) | 12 (7.6) | |||||
| PHQ-9, depression symptoms | |||||||||||||||||
| Normal | 347 (52.7) | 258 (53.2) | 89 (51.4) | .822 | 272 (52.7) | 75 (52.8) | .968 | 129 (56.6) | 218 (50.7) | .135 | 332 (52.9) | 15 (50.0) | .288 | 163 (50.4) | 94 (53.1) | 90 (57.0) | .072 |
| Mild | 166 (25.2) | 121 (25.0) | 45 (26.0) | 130 (25.2) | 36 (25.3) | 50 (21.9) | 116 (27.0) | 162 (25.8) | 4 (13.3) | 81 (25.1) | 50 (28.2) | 35 (22.2) | |||||
| Moderate | 84 (12.8) | 55 (11.3) | 29 (16.8) | 71 (13.8) | 13 (9.2) | 29 (12.7) | 55 (12.8) | 79 (12.6) | 5 (16.7) | 40 (12.4) | 24 (13.6) | 20 (12.6) | |||||
| Severe | 61 (9.3) | 51 (10.5) | 10 (5.8) | 43 (8.3) | 18 (12.7) | 20 (8.8) | 41 (9.5) | 55 (8.7) | 6 (20.0) | 39 (12.1) | 9 (5.1) | 13 (8.2) | |||||
| ISI, insomnia symptoms | |||||||||||||||||
| Normal | 309 (47.0) | 229 (47.2) | 80 (46.2) | .866 | 238 (46.1) | 71 (50.0) | .351 | 107 (46.9) | 202 (47.0) | .357 | 296 (47.1) | 13 (43.4) | .334 | 150 (46.9) | 79 (44.6) | 80 (50.6) | .173 |
| Mild | 238 (36.2) | 175 (36.1) | 63 (36.4) | 190 (36.8) | 48 (33.8) | 87 (38.2) | 151 (35.1) | 226 (36.0) | 12 (40.0) | 114 (35.6) | 66 (37.3) | 58 (36.7) | |||||
| Moderate | 85 (12.9) | 65 (13.4) | 20 (11.6) | 69 (13.4) | 16 (11.3) | 22 (9.6) | 63 (14.7) | 81 (12.9) | 4 (13.3) | 41 (12.8) | 26 (14.7) | 15 (9.5) | |||||
| Severe | 26 (3.9) | 16 (3.3) | 10 (5.8) | 19 (3.7) | 7 (4.9) | 12 (5.3) | 14 (3.2) | 25 (4.0) | 1 (3.3) | 15 (4.7) | 6 (3.4) | 5 (3.2) | |||||
| IES-R, distress symptoms | |||||||||||||||||
| Normal | 112 (17.0) | 84 (17.3) | 28 (16.2) | .484 | 78 (15.1) | 34 (23.9) | .210 | 39 (17.1) | 73 (17.0) | .698 | 109 (17.4) | 3 (10.0) | .099 | 50 (15.5) | 30 (16.9) | 32 (20.3) | .117 |
| Mild | 202 (30.7) | 151 (31.1) | 51 (29.5) | 164 (31.8) | 38 (26.8) | 73 (32.0) | 129 (30.0) | 195 (31.0) | 7 (23.4) | 96 (29.7) | 55 (31.1) | 51 (32.3) | |||||
| Moderate | 207 (31.5) | 153 (31.6) | 54 (31.2) | 166 (32.2) | 41 (28.9) | 72 (31.6) | 135 (31.4) | 197 (31.4) | 10 (33.3) | 100 (31.0) | 55 (31.1) | 52 (32.9) | |||||
| Severe | 137 (20.8) | 97 (20.0) | 40 (23.1) | 108 (20.9) | 29 (20.4) | 44 (19.3) | 93 (21.6) | 127 (20.2) | 10 (33.3) | 77 (23.8) | 37 (20.9) | 23 (14.5) | |||||
P value was calculated using the nonparametric Wilcoxon signed-rank test and Kruskal-Wallis test.
Abbreviations: BC = breast cancer; COVID-19 = coronavirus disease 2019; CVC = central venous catheter; GAD-7 = Generalized Anxiety Disorder Questionnaire; HER2 = human epidermal growth factor receptor 2; IES-R = Impact of Events Scale-Revised; ISI = Insomnia Severity Index; N/A = Not provided or not available; PHQ-9 = Patient Health Questionnaire; TNBC = triple negative breast cancer.
a
Single category included widowed and divorced participants.